Alkermes (ALKS) Insider Sale: EVP, Chief Legal Officer David Gaf
Alkermes (ALKS) EVP and Chief Legal Officer David Gaffin sold 2,034 shares on 2026-10-02, per SEC filing. He now owns 221,388 shares. Over the past year, he sold 18,306 shares with no purchases. The company had 29 insider sells and 0 buys in the same period. ALKS trades at $41.03, with a P/E of 108.44, above industry median and historical levels. GuruFocus values it at $32.72, deeming it 'Modestly Overvalued'.
How this was made
The 30-second read
Why it matters
The Form‑4 filing provides a fresh data point on insider sentiment but is unlikely to move the stock significantly given the modest size of the sale relative to float.
Market read
The filing is a primary disclosure of insider activity but carries limited trading relevance; it may marginally influence short‑term sentiment.
What to watch
The article does not disclose any change in the company's pipeline, earnings outlook, or financing needs that might contextualize the insider's decision.
Background
Alkermes is a Dublin‑based biopharmaceutical firm focused on CNS disorders. The stock trades at a high PE multiple and is currently rated modestly overvalued by GuruFocus.
Ticker impact
Executive Vice President and Chief Legal Officer David Gaffin sold 2,034 shares of Alkermes (ALKS) on 2026-10-02, adding to a year‑long pattern of insider selling with no purchases.
likely modest downside as investors price in continued insider sell‑off
Form‑4 filing is a primary source, but the transaction size is modest for an executive and the broader context shows no offsetting buys, suggesting limited but negative impact.
Market effects
Minimal; the biotech sector is unlikely to move on a single insider sale.
None; the filing is company‑specific and does not affect broader markets.
Low; no macro or cross‑border implications.
Counterpoint
Some investors may view the sale as a routine liquidity event rather than a negative signal, especially given the high valuation metrics that could still attract buyers.
Key entities
- ExecutiveDavid Gaffin
Executive Vice President and Chief Legal Officer of Alkermes who sold 2,034 shares.
- CompanyAlkermes PLC
Biopharmaceutical company (ticker ALKS) subject of the insider sale.
